|
| Primary information |
|---|
| ID | 10130 |
| Therapeutic ID | Th1018 |
| Protein Name | Secretin |
| Sequence | >Th1018_Secretin
HSDGTFTSELSRLREGARLQRLLQGLV
|
| Molecular Weight | 3039.44 |
| Chemical Formula | C130H220N44O40 |
| Isoelectric Point | 9.45 |
| Hydrophobicity | -0.463 |
| Melting point | NA |
| Half-life | 0.75 hours |
| Description | This drug is the synthetic form of natural secretin. It is prepared using solid phase peptide synthesis. Secretin is a peptide hormone produced in the S cells of the duodenum. Its main effect is to regulate the pH of the small intestine contents through the control of gastric acid secretion and buffering with bicarbonate. It was the first hormone to be discovered. |
| Indication/Disease | For diagnosis of pancreatic exocrine dysfunction and gastrinoma |
| Pharmacodynamics | Secretin is a hormone produced in the S cells of the duodenum in response to low local pH. It stimulates the secretion of bicarbonate from bicarbonate producing organs(liver, pancreas, Brunner's glands) when the pH drops below a set value. This helps neutralize the gastric acid entering the duodenum from the stomach. It also inhibits acid secretion from the stomach by reducing gastrin release from the G cells of the stomach. |
| Mechanism of Action | Secretin binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach. Binding leads to the secrection of bicarbonate or the reduction of the secretion of gastrin. Properly functioning organs (duodenum, pancreas and stomach) should be responsive to this hormone. |
| Toxicity | n acute toxicity studies with mice and rabbits, a dose of 20 μg/kg of synthetic human secretin was not lethal with no clinical symptoms of toxicity. |
| Metabolism | NA |
| Absorption | Following intravenous bolus administration of 0.4 mcg/kg, synthetic human secretin concentration rapidly declines to baseline secretin levels within 90 to 120 minutes |
| 2.7 L |
| Clearance | 580.9 ± 51.3 mL/min |
| Categories | Amino Acids, Peptides, and Proteins, Diagnostic Agents, Gastrointestinal Agents, Gastrointestinal Hormones, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Nerve Tissue Proteins, Neuropeptides, Peptide Hormones, Peptides, Proteins, Secretin, Secretin-class Hormone, Tests for Pancreatic Function |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Tiotropium.The stimulatory effect of Secretin may be reduced by anticholinergics such as Tiotropium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. |
| Target | NA |
| Brand Name | ChiRhoStim |
| Company | ChiRhoClin, Inc |
| Brand Description | ChiRhoClin, Inc |
| Prescribed For | Testing for stimulation of gastrin secretion to aid in the diagnosis of gastrinoma. |
| Chemical Name | NA |
| Formulation | As a 10 mL single-dose vial which contains 16 mcg of purified synthetic human secretin, 1.5 mg of Lcysteine hydrochloride, 20 mg of mannitol, and 9 mg of sodium chloride. When reconstituted in 8 mL of Sodium Chloride Injection USP, each mL of solution contains 2 mcg synthetic human secretin for intravenous use. The pH of the reconstituted solution has a range of 3 to 6.5. |
| Physical Appearance | white lyophilized sterile powder |
| Route of Administration | Intravenous infusion |
| Recommended Dosage | 0.2 mcg/kg by intravenous injection over 1 minute |
| Contraindication | NA |
| Side Effects | Nausea Vomiting Flushing Upset stomach |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |